Research programme: hepatitis C virus inhibitors - Progenics

Drug Profile

Research programme: hepatitis C virus inhibitors - Progenics

Alternative Names: PRO 206

Latest Information Update: 23 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Progenics Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 15 Mar 2012 Discontinued for Hepatitis C in USA (PO)
  • 23 Nov 2011 Research programme: hepatitis C virus inhibitors - Progenics is available for licensing as of 09 Nov 2011.
  • 18 Apr 2010 Pharmacodynamics data from a preclinical trial in Hepatitis C presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top